An article titled, “Comparison of Fracture Risk Following Semaglutide Treatment vs. Sleeve Gastrectomy,” was published in AACE Endocrinology and Diabetes by authors Jairo A. Noreñ, MD, C.William Pike, MD, Gavin Hui, MD, Yasaman Motlaghzadeh, MD-MPH, Deborah E. Sellmeyer, MD, Joy Y. Wu, MD-PHD, Sun H. Kim, MD MS. Dr. Noreñ, Dr. Motlaghzadeh, Dr. Sellmeyer, Dr. Wu, and Dr. Kim are affiliated with Stanford University School of Medicine. Dr. Pike and Dr. Hui are affiliated with Atropos Health.
Short Summary:
Weight loss in individuals with obesity offers metabolic benefits but may increase fracture risk, potentially influenced by the modality of weight loss. This study aimed to compare fracture risk in patients with obesity treated with semaglutide or sleeve gastrectomy (SG) using a large, real-world electronic health record (EHR) dataset.